

# **EXHIBIT 5**

1                   IN THE UNITED STATES DISTRICT COURT  
 2                   FOR THE NORTHERN DISTRICT OF OHIO  
 3                   EASTERN DIVISION

4                   - - -

5  
 6           IN RE:   NATIONAL                                 :   MDL NO. 2804  
 7           PRESCRIPTION OPIATE                         :  
           LITIGATION                                       :  
   :

-----  
 8           THIS DOCUMENT RELATES TO                 :   CASE NO.  
           ALL CASES                                       :   1:17-MD-2804  
 9   :  
   :   Hon. Dan A.  
 10    :   Polster

11                   - - -

12                   February 8, 2019

13                   - - -

14                   HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER  
 15                   CONFIDENTIALITY REVIEW

16                   Continued videotaped deposition  
 17           of CHRISTOPHER ZIMMERMAN taken pursuant to notice,  
           was held at the law offices of Reed Smith LLP, Three  
           Logan Square, 1717 Arch Street, Suite 3100,  
 18           Philadelphia, Pennsylvania, beginning at 1:44  
           p.m., on the above date, before Ann Marie  
 19           Mitchell, a Federally Approved Certified Realtime  
           Reporter, Registered Diplomate Reporter,  
 20           Registered Merit Reporter and Notary Public.

21                   - - -

22  
   :  
   :  
 23                   GOLKOW LITIGATION SERVICES  
                   877.370.3377 ph | 917.591.5672 fax  
   :  
   :  
 24                   deps@golkow.com

1 form.

2 THE WITNESS: Let me clarify.

3 It was a DEA conference in 2007.

4 It wasn't a HDA conference. It was a DEA  
5 conference. Sorry about that.

6 BY MR. PIFKO:

7 Q. So regardless of the type of  
8 conference, you had a discussion with other  
9 distributors at the end of 2007 about diversion  
10 control issues, which included whether they were  
11 implementing a shipping requirement?

12 A. I did a presentation on our  
13 program that had a requirement to not ship orders  
14 that we deemed to be suspicious, and they were  
15 present at the meeting.

16 Q. And they told you that that  
17 wasn't a requirement that any of them had?

18 A. I don't recall that being a  
19 specific statement. I don't remember the  
20 word-for-word conversation, but there was  
21 conversations about that process and whether it's  
22 legal and what the regulations imply, you know.  
23 Just general conversation.

24 Q. As part of this conference or on

1 Q. Have you ever discussed the  
2 quotas with any of your manufacturer clients or  
3 customers?

4 A. Not that I -- not that I know of.  
5 We -- you know, as a distributor, we don't deal  
6 with -- I mean, we're not involved in quotas.

7 Q. How about, have you ever heard of  
8 getting an allocation of a manufacturer's quota  
9 for distribution?

10 A. I'm not sure -- I know we get  
11 allocated product on short supply items. I'm not  
12 sure if that's what you're referencing.

13 Q. Have you ever like, for example,  
14 applied to get a certain percentage of the  
15 distribution of Schedule II controlled substances  
16 manufactured by like Purdue?

17 A. I wouldn't know that.

18 Q. Who would know that?

19 A. If it's a purchasing or  
20 procurement, then it would be that -- global  
21 sourcing is the name of the department that does  
22 all the buying for the company.

23 Q. Item number 2 here says, "DEA  
24 issued registrations to pill mills that 'popped